Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 16/20 | 0.78 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9885620 | 0.86 | CXCR4 (0.57) | CXCR4CXCL12SMN1; SMN2SCN8A | |
| SCHEMBL9885505 | 0.84 | CXCR4 (0.76) | CXCR4CXCL12SCN8A | |
| SCHEMBL2579002 | 0.84 | HRH3 (0.66) | CXCR4CXCL12SMN1; SMN2HRH3NPC1 | |
| SCHEMBL11432052 | 0.82 | HRH3 (0.62) | CXCR4CXCL12SMN1; SMN2HRH3NPC1 | |
| SCHEMBL9885528 | 0.81 | CXCR4 (0.85) | CXCR4CXCL12HRH3 | |
| SCHEMBL9884894 | 0.78 | CXCR4 (0.78) | CXCR4CXCL12HRH3 | |
| SCHEMBL9884616 | 0.78 | CXCR4 (0.78) | CXCR4CXCL12HRH3 | |
| SCHEMBL22379954 | 0.78 | CXCR4 (0.78) | CXCR4CXCL12HRH3 | |
| SCHEMBL9884637 | 0.76 | CXCR4 (0.74) | CXCR4CXCL12HRH3 | |
| SCHEMBL9885619 | 0.76 | SCN8A (0.55) | CXCR4CXCL12HRH3SCN8A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200268729-A1 | NOVEL CXCR4 ANTAGONISTS WITH AMINO ACID SKELETON, PREPARATION THEREFOR AND BIOMEDICAL USE THEREOF | TSINGHUA UNIVERSITY (CN) | 2020-08-27 | — | — | US | disclosed |
| EP-1890703-B1 | PYRIMIDINE COMPOUNDS AS CHEMOKINE RECEPTORS INHIBITORS | TAIGEN BIOTECHNOLOGY CO LTD (TW) | 2016-05-11 | — | — | EP | disclosed |
| US-8372849-B2 | Heterocyclic compounds | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2013-02-12 | — | — | US | disclosed |
| US-8193206-B2 | Pyrimidine compounds | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2012-06-05 | — | — | US | disclosed |
| WO-2009131598-A1 | HETEROCYCLIC COMPOUNDS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2009-10-29 | — | — | WO | disclosed |
| US-20090264339-A1 | Heterocyclic Compounds | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2009-10-22 | — | — | US | disclosed |
| US-7589197-B2 | Pyrimidine compounds | TAIGEN BIOTECHNOLOGY (TW) | 2009-09-15 | — | — | US | disclosed |
| US-20090143302-A1 | PYRIMIDINE COMPOUNDS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200268729-A1 | NOVEL CXCR4 ANTAGONISTS WITH AMINO ACID SKELETON, PREPARATION THEREFOR AND BIOMEDICAL USE THEREOF | CXCR4, CXCL12, CXCR1 | CXCR4 1/4885CXCL12 2/4885SMN1; SMN2 4352/4885 |
| US-20090143302-A1 | PYRIMIDINE COMPOUNDS | TYMS, TYMP, HPRT1 | CXCR4 247/4885CXCL12 109/4885SMN1; SMN2 252/4885 |
| US-20090264339-A1 | Heterocyclic Compounds | AHR, NQO1, LTC4S | CXCR4 125/4885CXCL12 103/4885SMN1; SMN2 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.